Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Richard Pacher

Showing results (31-40 of 89) with videos related to

Pageof 9
Sort By:
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|June 24, 2003
Clinical benefit of prostaglandin E1-treatment of patients with ischemic heart disease: stimulation of therapeutic angiogenesis in vital and infarcted myocardiumMohammad Reza Mehrabi, Nermin Serbecic, Forouzan Tamaddon, et al.
Transplantation|December 14, 2006
Heart transplantation provides long-term survival benefit in stable patients experiencing heart failure without reverse left ventricular remodelingBrigitte Meyer, Deddo Moertl, Martin Huelsmann, et al.
Clinical Chemistry|November 4, 2009
Prognostic value of emerging neurohormones in chronic heart failure during optimization of heart failure-specific therapyStephanie Neuhold, Martin Huelsmann, Guido Strunk, et al.
Clinical Chemistry|March 18, 2006
Midregional pro-A-type natriuretic peptide measurements for diagnosis of acute destabilized heart failure in short-of-breath patients: comparison with B-type natriuretic peptide (BNP) and amino-terminal proBNPAlfons Gegenhuber, Joachim Struck, Werner Poelz, et al.
European Journal of Clinical Investigation|November 13, 2010
Cost analysis and cost-effectiveness of NT-proBNP-guided heart failure specialist care in addition to home-based nurse careChristopher Adlbrecht, Martin Huelsmann, Rudolf Berger, et al.
European Journal of Heart Failure|March 12, 2004
Muscle strength as a predictor of long-term survival in severe congestive heart failureMartin Hülsmann, Michael Quittan, Rudolf Berger, et al.
European Journal of Clinical Investigation|November 6, 2015
Outcome of conservative management vs. assist device implantation in patients with advanced refractory heart failureChristopher Adlbrecht, Martin Hülsmann, Raphael Wurm, et al.
The American Journal of Cardiology|July 13, 2004
Effect of single doses of SLV306, an inhibitor of both neutral endopeptidase and endothelin-converting enzyme, on pulmonary pressures in congestive heart failureKenneth Dickstein, Hanka J De Voogd, Milutin P Miric, et al.
Journal of Cardiac Failure|March 7, 2007
Comparative evaluation of B-type natriuretic peptide, mid-regional pro-A-type natriuretic peptide, mid-regional pro-adrenomedullin, and Copeptin to predict 1-year mortality in patients with acute destabilized heart failureAlfons Gegenhuber, Joachim Struck, Benjamin Dieplinger, et al.
Journal of the American College of Cardiology|May 9, 2009
Comparison of midregional pro-atrial and B-type natriuretic peptides in chronic heart failure: influencing factors, detection of left ventricular systolic dysfunction, and prediction of deathDeddo Moertl, Rudolf Berger, Joachim Struck, et al.
Pageof 9

Showing results (31-40 of 89) with videos related to

Sort By:
Pageof 9
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|June 24, 2003
Clinical benefit of prostaglandin E1-treatment of patients with ischemic heart disease: stimulation of therapeutic angiogenesis in vital and infarcted myocardiumMohammad Reza Mehrabi, Nermin Serbecic, Forouzan Tamaddon, et al.
Transplantation|December 14, 2006
Heart transplantation provides long-term survival benefit in stable patients experiencing heart failure without reverse left ventricular remodelingBrigitte Meyer, Deddo Moertl, Martin Huelsmann, et al.
Clinical Chemistry|November 4, 2009
Prognostic value of emerging neurohormones in chronic heart failure during optimization of heart failure-specific therapyStephanie Neuhold, Martin Huelsmann, Guido Strunk, et al.
Clinical Chemistry|March 18, 2006
Midregional pro-A-type natriuretic peptide measurements for diagnosis of acute destabilized heart failure in short-of-breath patients: comparison with B-type natriuretic peptide (BNP) and amino-terminal proBNPAlfons Gegenhuber, Joachim Struck, Werner Poelz, et al.
European Journal of Clinical Investigation|November 13, 2010
Cost analysis and cost-effectiveness of NT-proBNP-guided heart failure specialist care in addition to home-based nurse careChristopher Adlbrecht, Martin Huelsmann, Rudolf Berger, et al.
European Journal of Heart Failure|March 12, 2004
Muscle strength as a predictor of long-term survival in severe congestive heart failureMartin Hülsmann, Michael Quittan, Rudolf Berger, et al.
European Journal of Clinical Investigation|November 6, 2015
Outcome of conservative management vs. assist device implantation in patients with advanced refractory heart failureChristopher Adlbrecht, Martin Hülsmann, Raphael Wurm, et al.
The American Journal of Cardiology|July 13, 2004
Effect of single doses of SLV306, an inhibitor of both neutral endopeptidase and endothelin-converting enzyme, on pulmonary pressures in congestive heart failureKenneth Dickstein, Hanka J De Voogd, Milutin P Miric, et al.
Journal of Cardiac Failure|March 7, 2007
Comparative evaluation of B-type natriuretic peptide, mid-regional pro-A-type natriuretic peptide, mid-regional pro-adrenomedullin, and Copeptin to predict 1-year mortality in patients with acute destabilized heart failureAlfons Gegenhuber, Joachim Struck, Benjamin Dieplinger, et al.
Journal of the American College of Cardiology|May 9, 2009
Comparison of midregional pro-atrial and B-type natriuretic peptides in chronic heart failure: influencing factors, detection of left ventricular systolic dysfunction, and prediction of deathDeddo Moertl, Rudolf Berger, Joachim Struck, et al.
Pageof 9